Vasoactive Peptides, their Receptors and Drug Development

Basic and Clinical Pharmacology and Toxicology

Volumn 94, Issue 1, 2004, Pages 5-12

  Kusserow, Heike ^a   Unger, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ATRASENTAN; BOSENTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; G PROTEIN COUPLED RECEPTOR; SITAXSENTAN; TEZOSENTAN; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; ENDOTHELIN RECEPTOR;

DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; GENE TARGETING; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; VASOCONSTRICTION; ANIMAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ENDOTHELINS; HUMANS; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTOR AGENTS;

EID: 1642334069     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2004.pto_940103.x     Document Type: Short Survey

References (100)

1. Akishita, M., M. Iwai, L. Wu, L. Zhang, Y. Ouchi, V. J. Dzau & M. Horiuchi: Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 2000, 102, 684-689.
2. Anand, I. S. & T. F. Lüscher: The earth trial. Press release, XXIV Congress European Society of Cardiology, Berlin, 2002.
3. Baynash, A. G., K. Hosoda, A. Giaid, J. A. Richardson, N. Emoto, R. E. Hammer & M. Yanagisawa: Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 1994, 79, 1277-1285.
4. Benigni, A: Endothelin antagonists in renal disease. Kidney Int. 2000, 57, 1778-1794.
5. Beril, T., A. Dendorfer & A. H. J. Danser: Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int. J. Biochem. Cell Biol. 2003, 35, 792-801.
6. Booz, G. W. & K. M. Baker: Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996, 28, 635-640.
7. Brede, M., K. Hadamek, L. Meinel, F. Wiesmann, J. Peters, S. Engelhardt, A. Simm, A. Haase, M. J. Lohse & L. Hein: Vascular hypertrophy and increased P70S6 kinase in mice lacking the angiotensin II AT(2) receptor. Circulation 2001, 104, 2602-2607.
8. Busche, S., S. Gallinat, R. M. Bohle, A. Reinecke, J. Seebeck, F. Franke, L. Fink, M. Zhu, C. Sumners & T. Unger: Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Amer. J. Pathol. 2000, 157, 605-611.
9. Campbell, D. J.: Vasopeptidase inhibition: a double-edged sword? Hypertension 2003, 41, 383-389.
10. Carducci, M. A., R. J. Padley, J. Breul, N. J. Vogelzang, B. A. Zonnenberg, D. D. Daliani, C. C. Schulman, A. A. Nabulsi, R. A. Humerickhouse, M. A. Weinberg, J. L. Schmitt & J. B. Nelson: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J. Clin. Oncol. 2003, 21, 679-689.
11. Ceccherini, I., A. L. Zhang, I. Matera, G. Yang, M. Devoto, G. Romeo & D. T. Cass: Interstitial deletion of the endothelin-B receptor gene in the spotting lethal (sl) rat. Hum. Mol. Genet., 1995, 4, 2089-2096.
12. Channick, R. N., G. Simonneau, O. Sitbon, I. M. Robbins, A. Frost, V. F. Tapson, D. B. Badesch, S. Roux, M. Rainisio, F. Bodin & L. J. Rubin: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonrary hypertension: a randomised placebo-controlled study. Lancet 2001, 358, 1119-1123.
13. Chen, X., W. Li, H. Yoshida, S. Tsuchida, H. Nishimura, F. Takemoto, S. Okubo, A. Fogo, T. Matsusaka & I. Ichikawa: Targeted deletion of angiotensin type 1B receptor gene in the mouse. Amer. J. Physiol. 1997, 272, F299-304.
14. Chen, Y. F. & S. Oparil: Endothelin and pulmonary hypertension. J. Cardiovasc. Pharmacol. 2000, 35(4, Suppl. 2), S49-S53.
15. Clouthier, D. E., K. Hosoda, J. A. Richardson, S. C. Williams, H. Yanagisawa, T. Kuwaki, M. Kumada, R. E. Hammer & M. Yanagisawa: Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 1998, 125, 813-824.
16. Coats, A. J.: Omapatrilat - the story of Overture and Octave. Int. J. Cardiol. 2002, 86, 1-4.
17. Davenport, A. P.: International Union of Pharmacology: XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev. 2002, 54, 219-226.
18. Davenport, A. P. & J. J. Maguire: Of mice an men: advance in endothelin research and first antagonist gains FDA approval. Trends Pharmacol. Sci. 2002, 23, 155-157.
19. De Gasparo, M., K. J. Catt, T. Inagami, J. W. Wright & T. Unger: International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52, 415-472.
20. Dimmeler, S., V. Rippmann, U. Weiland, J. Haendeler & A. M. Zeiher: Angiotensin II induces apoptosis of human endothelial cells: protective effect of nitric oxide. Circ. Res. 1997, 81, 970-976.
21. Dzau, V. J. & G. H. Gibbons: Autocrine and paracrine mechanisms of vascular myocytes in systemic hypertension. Amer. J. Cardiol. 1987, 60, 991-1031.
22. Emori, T., Y. Hirata, K. Ohta, K. Kanno, S. Eguchi, T. Imai, M. Shichiri & F. Marumo: Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991, 18, 165-170.
23. Esther, C. R. Jr., T. E. Howard, E. M. Marino, J. M. Goddard, M. R. Capecchi & K. E. Bernstein: Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab. Invest 1996, 74, 953-965.
24. Gallinat, S., M. Yu, A. Dorst, T. Unger & T. Herdegen: Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res. Mol. Brain Res. 1998, 57, 111-122.
25. Gallinat, S., S. Busche, M. K. Raizada & C. Sumners: The angiotensin II type 2 receptor: an enigma with multiple variations. Amer. J. Physiol. Endocrinol. Metab. 2000, 278, E357-374.
26. Givertz, M. M., W. S. Colucci, T. H. LeJemtel, S. S. Gottlieb, J. M. Hare, M. T. Slawsky, C. V. Leier, E. Loh, J. M. Nicklas & B. E. Lewis: Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure.-Circulation 2000, 101, 2922-2927.
27. Gray, M. O., C. S. Long, J. E. Kalinyak, H. T. Li & J. S. Karliner: Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc. Res. 1998, 40, 352-363.
28. Griffin, S. A., W. C. Brown, F. MacPherson, J. C. McGrath, V. G. Wilson, N. Korsgaard, M. J. Mulvany & A. F. Lever: Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991, 17, 626-635.
29. Hein, L., G. S. Barsh, R. E. Pratt, V. J. Dzau & B. K. Kobilka: Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995, 377, 744-747.
30. Heudi, O., C. Ramirez-Molina, P. Marshall, A. Amour, S. Peace, S. McKeown & F. Abou-Shakra: Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat. J. Pept. Sci., 2002, 8, 591-600.
31. Higgins, R. D., K. D. Hendricks-Munoz, V. V. Caines, R. P. Gerrets & D. B. Rifkin: Hyperoxia stimulates endothelin-1 secretion from endothelial cells; modulation by captopril and nifedipine. Curr. Eye Res. 1998, 17, 487-493.
32. Horiuchi, M., M. Akishita & V. J. Dzau: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension, 1999, 33, 613-621.
33. Hosoda, K., R. E. Hammer, A. Giaid, J. A. Richardson, A. G. Baynash, J. C. Cheung & M. Yanagisawa: Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 1994, 79, 1267-1276.
34. Ichiki, T., P. A. Labosky, C. Shiota, S. Okuyama, Y. Imagawa, A. Fogo, F. Niimura, I. Ichikawa, B. L. Hogan & T. Inagami: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377, 748-750.
35. Ichihara, S., T. Senbonmatsu, E. Price Jr., T. Ichiki, F. A. Gaffney & T. Inagami: Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation 2002, 106, 2244-2249.
36. Janiak, P., A. Pillon, J. F. Prost & J. P. Vilaine: Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992, 20, 737-745.
37. Kalra, P. R., J. C. C. Moon & A. J. S. Coats: Do results of the ENABLE (endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol. 2002, 85, 195-197.
38. Kaluski, E., I. Kobrin, R. Zimlichman, A. Marmor, O. Krakov, O. Milo, A. Frey, S. Kaplan, R. Krakover, A. Caspi, Z. Vered, G. Cotter: RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J. Amer. Coll. Cardiol. 2003, 41, 204-210.
39. Kambayashi, Y., S. Bardhan, K. Takahashi, S. Tsuzuki, H. Inui, T. Hamakubo & T. Inagami: Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268, 24543-24546.
40. Kaschina, E. & T. Unger. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003, 12, 70-88.
41. Kempf, H., C. Linares, P. Corvol, J. M. Gasc & D. E. Kohan: Endothelins in the kidney: physiology and pathophysiology. Amer. J. Kidney Dis. 1993, 22, 493-510.
42. Kim, H. S., J. H. Krege, K. D. Kluckman, J. R. Hagaman, J. B. Hodgin, C. F. Best, J. C. Jennette, T. M. Coffman, N. Maeda & O. Smithies: Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl. Acad. Sci. USA 1995, 92, 2735-2739.
43. Krege, J. H., S. W. John, L. L. Langenbach, J. B. Hodgin, J. R. Hagaman, E. S. Bachman, J. C. Jennette, D. A. O'Brien & O. Smithies: Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995, 375, 146-148.
44. Krum, H., R. J. Viskoper, Y. Lacourciere, M. Budde & V. Charlon: The effect of an endothelin-receptor antagonist, Bosentan, on blood pressure in patients with essential hypertension. J. Hypertens. 1998, 12, 1069-1074.
45. Kurihara, Y., H. Kurihara, H. Suzuki, T. Kodama, K. Maemura, R. Nagai, H. Oda, T. Kuwaki, W. H. Cao, N. Ikamada, K. Jishage, Y. Ouchi, S. Azuma, Y. Toyoda, T. Ishikawa, M. Kumada & Y. Yazaki: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994, 368, 703-710.
46. Lopez, J. J., B. H. Lorell, J. R. Ingelfinger, E. O. Winberg, H. Schunkert, D. Diamant & S. S. Tang: Distribution and function of cardiac angiotensin AT1- and AT2 receptor subtypes in hypertrophied rat hearts. Amer. J. Physiol. 1994, 267, 844-852.
47. Louis, A., J. G. Cleland, S. Crabbe, S. Ford, S. Thackray, T. Houghton & A. Clark: Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER, and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology. Eur. J. Heart Failure 2001, 3, 381-387.
48. Lucius, R., S. Gallinat, P. Rosenstiel, T. Herdegen, J. Sievers & T. Unger: The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J. Exp. Med. 1998, 188, 661-670.
49. Luscher, T. F., F. Enseleit, R. Pacher, V. Mitrovic, M. R. Schulze, R. Willenbrock, R. Dietz, V. Rousson, D. Hurlimann, S. Philipp, T. Notter, G. Noll & F. Ruschitzka: Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002, 106, 2666-2672.
50. Maki, T., Y. Nasa, K. Tanonaka, M. Takahashi & S. Takeo: Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J. Pharmacol. Exp. Therap. 2003, 305, 97-105.
51. Malek, A. & S. Izumo: Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Amer. J. Physiol. 1992, 263, C389-C396.
52. Markewitz, B. A., D. E. Kohan & J. R. Michael: Endothelin-1 synthesis, receptors, and signal transduction in alveolar epithelium: evidence for an autocrine role. Amer. J. Physiol. 1995, 268, L192-200.
53. 2receptor. Kidney Int. 1998, 53, 92-99.
54. Matsumura, Y., T. Kuro, Y. Kobayashi, K. Umekawa, N. Ohashi & M. Takaoka: Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats. Jap. J. Pharmacol. 2000, 84, 16-24.
55. Matsumura, Y., S. Murata, K. Takada, M. Takaoka & S. Morimoto: Involvement of transforming growth factor-beta 1 for platelets-induced stimulation of endothelin-1 production. Clin. Exp. Pharmacol. Physiol. 1994, 21, 991-996.
56. McMurray, J. & M. A. Pfeffer: New therapeutic options in congestive heart failure: part I. Circulation 2002, 105, 2099-2106.
57. Meffert, S., M. Stoll, U. M. Steckelings, S. P. Bottari & T. Unger: The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 1996, 122, 59-67.
58. Naccarella, F., G. V. Naccarelli, S. S. Maranga, G. Lepera, M. C. Grippo, F. Melandri, M. Gatti, S. Pazzaglia, G. Spinelli, V. Angelini, E. Ambrosioni, C. Borghi, M. T. Giovagnorio & S. Nisam: Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials. Curr. Opin. Cardiol. 2002, 17, 6-18.
59. Nakajima, M., M. Mukoyama, R. E. Pratt, M. Horiuchi & V. J. Dzau: Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 1993, 197, 393-399.
60. Nakov, R., E. Pfarr & S. Eberle: Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Amer. J. Hypertens. 2002, 15, 583-589.
61. Nelson J. B., K. Chan-Tack, S. P. Hedican, S. R. Magnuson, T. J. Opgenorth, G. S. Bova & J. W. Simons: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996, 56, 663-668.
62. Nio, Y., H. Matsubara, S. Murasawa, M. Kanasaki & M. Inada: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J. Clin. Invest. 1995, 95, 46-54.
63. O'Connor, C. M., W. A. Gattis, K. F. Adams Jr., M. R. Shah, I. Kobrin, A. Frey & M. Gheorghiade: Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). Amer. Heart J. 2002, 144, 583-588.
64. Ohuchi, T., T. Kuwaki, G. Y. Ling, D. Dewit, K. H. Ju, M. Onodera, W. H. Cao, M. Yanagisawa & Kumada: Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am. J. Physiol. 1999, 276, R1071-R1077.
65. Oliverio, M. I., H. S. Kim, M. Ito, T. Le, L. Audoly, C. F. Best, S. Hiller, K. Kluckman, N. Maeda, O. Smithies & T. M. Coffman: Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc. Natl. Acad. Sci. USA 1998, 95, 15496-15501.
66. Ozono, R., Z. Q. Wang, A. F. Moore, T. Inagami, H. M. Siragy & R. M. Carey: Expression of the subtype 2 angiotensin AT2 receptor protein in rat kidney. Hypertension 1997, 30, 1238-1246.
67. Packer, M.: Multicentre, couble-blind, placebo controlled study of long-term endothelin blockade with bosentan in chronic heart failure - results of the REACH-1 trial. Circulation 1998, 98, 13.
68. Packer, M, R. M. Califf, M. A. Konstam, H. Krum, J. J. McMurray, J. L. Rouleau & K. Swedberg: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002, 106, 920-926.
69. Piuhola, J, I. Szokodi, P. Kinnunen, M. Ilves, R. deChatel, O. Vuolteenaho & H. Ruskoaho: Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts. Hypertension 2003, 41, 93-98.
70. Puffenberger, E. G., K. Hosoda, S. S. Washington, K. Nakao, D. DeWit, M. Yanagisawa & A. Chakravarti. A missence mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 1994, 79, 1257-1266.
71. Remuzzi, G., N. Perico & A. Benigni: New therapeutics that antagonize endothelin: promises and frustrations. Nature Rev. Drug Disc. 2002, 1, 986-1000.
72. Rubin, L. J., D. B. Badesch, R. J. Barst, N. Galie, C. M. Black, A. Keogh, T. Pulido, A. Frost, S. Roux S, I. Leconte, M. Landzberg & G. Simonneau: Bosentan therapy for pulmonary arterial hypertension. New Engl. J. Med. 2002, 346, 896-903.
73. Seed, A., M. P. Love & J. J. McMurray: Clinical experience with endothelin receptor antagonists in chronic renal failure. Heart Failure Rev. 2001, 6, 317-323.
74. Shanmugam, S. & K. Sandberg: Ontogeny of angiotensin II receptors. Cell Biol Int. 1996, 20, 169-176.
75. Spieker, L. E., G. Noll, F. T. Ruschitzka & T. F. Luscher: Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future. J. Amer. Coll. Cardiol. 2001, 37, 1493-1505.
76. Stanton, A., J. Barton, C. Jensen, B. Bibillier, J. Mann & E O'Brien: Dose response antihypertensive efficacy of aliskiren (SPP100), an orally active renin inhibitor. Amer. J. Hypertens. 2002, 15 (Suppl. 1), A56-A57.
77. Stoll, M., U. M. Steckelings, M. Paul, S. P. Bottari, R. Metzger & T. Unger: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. 1995a, 95, 651-7.
78. Stoll, M., S. Meffert, U. Stroth & T. Unger: Growth or antigrowth: angiotensin and the endothelium. J. Hypertens. 1995b, 13, 1529-1534.
79. Sugaya, T., S. Nishimatsu, K. Tanimoto, E. Takimoto, T. Yamagishi, K. Imamura, S. Goto, K. Imaizumi, Y. Hisada, A. Otsuka, H. Uchida, M. Sugiura, K. Fukuta, A. Fukamizu & K. Murakami: Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 1995, 270, 18719-18722.
80. Svensson, P. J., D. von Tell, M. L. Molander, M. Anvret & A. A. Nordenskjold: Heterozygous frameshift mutation in the endothelin-3 (EDN-3) gene in isolated Hirschsprung's disease. Pediatr. Res. 1999, 45, 714-717.
81. Takahashi, T., T. Kanda, M. Inoue, H. Sumino, I. Kobayashi, A. Iwamoto & R. Nagai: Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sci. 1998, 63, PL137-143.
82. Takasaki, C., N. Tamiya, A. Bdolah, Z. Wollberg & E. Kochva: Sarafotoxins S6, several isotoxins from Atractaspis engaddensis (burrowing asp) venom that affect the heart. Toxicon 1988, 26, 543-548.
83. Tanaka, H., K. Moroi, J. Iwai, H. Takahashi, N. Ohnuma, S. Hori, M. Takimoto, M. Nishiyama, T. Masaki, M. Yanagisawa, S. Sekiya & S. Kimura: Novel mutations of the endothelin B receptor gene in patients with Hirschsprung's disease and their characterization. J. Biol. Chem. 1998, 273, 11378-11383.
84. Tanimoto, K., F. Sugiyama, Y. Goto, J. Ishida, E. Takimoto, K. Yagami, A. Fukamizu & K. Murakami: Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 1994, 269, 31334-31347.
85. Treinen, K. A., C. Louden, M. J. Dennis & P. J. Wier: Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 1999, 59, 51-59.
86. Tsuchida, S., T. Matsusaka, X. Chen, S. Okubo, F. Niimura, H. Nishimura, A. Fogo, H. Utsunomiya, T. Inagami T & I. Ichikawa: Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J. Clin. Invest. 1998, 101, 755-760.
87. Unger, T., E. Badoer, D. Ganten, R. E. Lang, & R. Rettig: Brain angiotensin: Pathways and pharmacology. Circulation 1988, 77 (Suppl. 1), 40-54.
88. Unger, T. & P. Gohlke: Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc. Res. 1994, 2, 146-158.
89. Unger, T.: The angiotensin type 2 receptor: variations on an enigmatic theme. J. Hypertens. 1999, 17, 1775-1786.
90. van Wamel, A. J., C. Ruwhof, L. E. van der Valk-Kokshoom, P. I. Schrier & A. van der Laarse: The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol. Cell Biochem. 2001, 218, 113-124.
91. Viswanathan, M. & J. M. Saavedra: Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides 1992, 13, 783-786.
92. Weber, K. T., Y. Sun & S. E. Campbell: Structural remodelling of the heart by fibrous tissue: Role of circulating hormones and locally produced peptides. Eur. Heart J. 1995a, 16 (Suppl. N), 12-18.
93. Weber, K. T., Y. Sun, L. C. Katwa & J. P. M. Cleutjens: Connective tissue - a metabolic entity. J. Mol. Cell. Cardiol. 1995b, 27, 107-120.
94. Wood, J. M., J. Maibaum, J. Rahuel, M. G. Grutter, N. C. Cohen, V. Rasetti, H. Ruger, R. Goschke, S. Stutz, W. Fuhrer, W. Schilling, P. Rigollier, Y. Yamaguchi, F. Cumin, H. P. Baum, C. R. Schnell, P. Herold, R. Mah, C. Jensen, E. O'Brien, A. Stanton & M. P. Bedigian. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 2003, 308, 698-705.
95. Yamada, T., M. Horiuchi & V. J. Dzau: Angiotensin type II receptor mediates programmed cell death. Proc. Natl. Acad Sci. USA 1996, 93, 156-160.
96. Yamada, T., M. Akishita, M. J. Pollman, G. H. Gibbons, V. J. Dzau & M. Horiuchi: Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci. 1998, 63, PL289-295.
97. Yanagisawa, M., H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto & T. Masaki: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332, 411-415.
98. Yanagisawa, H., R. E. Hammer, J. A. Richardson, N. Emoto, S. C. Williams, S. Takeda, D. E. Clouthier & M. Yanagisawa: Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J. Clin. Invest. 2000, 105, 1373-1382.
99. Zaman, M. A., S. Oparil & D. A. Calhoun: Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov. 2002, 1, 621-636.
100. Zhu, Y. Z., Y. C. Zhu, J. Li, H. Schäfer, W. Schmidt, T. Yao & T. Unger: Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction. J. Renin Angiotensin Aldosterone Syst. 2000, 1, 257-262.